- Home
- AHG vs QURE Comparison
AHG vs QURE Comparison
Compare AHG & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AHG | QURE |
|---|---|---|
| Founded | 2013 | 1998 |
| Country | China | Netherlands |
| Employees | N/A | 248 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2017 | 2013 |
Fundamental Metrics
Financial Performance| Metric | AHG | QURE |
|---|---|---|
| Price | $1.32 | $46.28 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $45.00 |
| AVG Volume (30 Days) | 6.7K | ★ 1.3M |
| Earning Date | 08-14-2025 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | N/A | $126.12 |
| Revenue Next Year | N/A | $200.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.10 | $8.73 |
| 52 Week High | $2.50 | $71.50 |
Technical Indicators
Market Signals| Indicator | AHG | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 38.85 | 64.12 |
| Support Level | $1.24 | $21.16 |
| Resistance Level | $1.64 | $50.47 |
| Average True Range (ATR) | 0.11 | 2.14 |
| MACD | -0.02 | 0.32 |
| Stochastic Oscillator | 6.64 | 99.80 |
Price Performance
Historical ComparisonAbout AHG Akso Health Group ADS
Akso Health Group is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.